Following his education at Izmir Private Çakabey Highschool, Dr. Yandım obtained his BSc. in Molecular Biology and Genetics from Bilkent University. He conducted research at Harvard University Medical School as well as University of Texas Southwestern Medical Center, where he performed research on gene control and immunology. His emerging interest in gene control and epigenetics paved the way for him to do a PhD in this field at Imperial College London, where he was supported by a full scholarship from the Medical Research Council of United Kingdom. His findings on reversing gene dysregulation in an incurable form of ataxia led him to pursue an exploratory clinical trial. He published the results of this study as a first co-author in the medical journal Lancet, which is the third top ranked academic journal in the world with an impact factor of 53.2 . He continued his postdoctoral studies also in London at the Institute of Cancer Research, where he studied signal transduction in cancer. He is currently focused on revealing the interplay between repetitive DNA and cancer.

All of his research articles were published in SCI and Web of Science indexed international journals. His research has been cited 164 times according to Web of Science and 280 times according to Google Scholar (as of August 2019). Dr. Yandım is an honorary associate at Izmir Biomedicine and Genome Center (iBG).